Japan Tissue Engineering Co

Japan Tissue Engineering Co Current Liabilities

Current Liabilities of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026.

Current Liabilities

-JPY

Last updated:

Current Liabilities of Japan Tissue Engineering Co is 2026 - JPY. Current Liabilities of Japan Tissue Engineering Co was 2025 - JPY. It decreases by % lower compared to the previous year.

The Japan Tissue Engineering Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2004
516.10 M JPY
Jan 1, 2005
480.20 M JPY
Jan 1, 2015
409.97 M JPY
Jan 1, 2016
555.41 M JPY
Jan 1, 2017
555.30 M JPY
Jan 1, 2018
807.47 M JPY
Jan 1, 2019
920.82 M JPY
Jan 1, 2020
911.44 M JPY
The Japan Tissue Engineering Co Current Liabilities history
YEARCurrent LiabilitiesYoY
911.44 MJPY-1.02%
920.82 MJPY+14.04%
807.47 MJPY+45.41%
555.30 MJPY-0.02%
555.41 MJPY+35.48%
409.97 MJPY-14.63%
480.20 MJPY-6.96%
516.10 MJPY+378.76%
107.80 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

On Eulerpool you can find the complete historical development of Current Liabilities Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Japan Tissue Engineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co